Hanmi Pharm
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
45 Bangi-dong, Seoul, South KoreaPhone Number
+82 24109114Website
www.hanmi.co.krRevenue
$7.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Hanmi Pharm
Hanmi Pharmaceutical focuses on an open R&D strategy and diversifies its global strategy. The company innovates distribution through RFID technology and secures a pipeline of new drugs, including global and combination drugs. Hanmi aims to advance its pharmaceutical distribution systems to enhance efficiency and effectiveness. Their intended clients include healthcare providers and patients seeking innovative pharmaceutical solutions.Explore more
Hanmi Pharm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hanmi Pharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Hanmi Pharm, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hanmi Pharm is spiking on competitors!
Earning: See what the market has to say on Hanmi Pharm recently announced quarterly report
Funding: Get notified immidiatlly once Hanmi Pharm has new funding data
Product Launch: Get notified when Hanmi Pharm launches new products
Click to see if Hanmi Pharm had a recent Job posting/layoffs
Check if Hanmi Pharm has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Hanmi Pharm
Recommended Actions
Reach out to Masked Content who joined Hanmi Pharm as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Hanmi Pharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hanmi Pharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hanmi Pharm.
Hanmi Pharm Tech Stack
Hanmi Pharm News & Media
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") and Health Hope Pharma ("HHP") granting Gilead the exclusive rights to develop and commercialize encequidar. Orascovery™ is an innovative oral drug delivery proprietary platform owned by Hanmi that eHanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy
Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) underway SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi PharHanmi Pharmaceutical's board of directors rejected the appointment of its founder's eldest son, Im J..
Hanmi Pharmaceutical's board of directors rejected the appointment of its founder's eldest son, Im Jong-yoon, as its CEO. This will also strengthen Hanmi Pharmaceutical's independent management system..Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 24, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hanmi Pharm
Sign Up For FreeTo access detailed company insights
Hanmi Pharmaceutical focuses on an open R&D strategy and diversifies its global strategy. The company innovates distribution through RFID technology and secures a pipeline of new drugs, including global and combination drugs. Hanmi aims to advance its pharmaceutical distribution systems to enhance efficiency and effectiveness. Their intended client... Read More
